Drugs / NPX372
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07563829 | Apr 2026 → Apr 2027 expected | metastatic malignant neoplasm | NextPoint Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | NextPoint Therapeutics, Inc. | Regulatory NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors nextpointtx.com ↗ |
| 2024-11-07 | NextPoint Therapeutics, Inc. | Results NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024 nextpointtx.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-09 | NextPoint Therapeutics, Inc. | NextPoint Therapeutics Announces Clinical Entry of NPX372, a First-in-Class B7-H7–Targeted T Cell Engager to Treat Solid Tumors nextpointtx.com ↗ |
| 2024-11-07 | NextPoint Therapeutics, Inc. | NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024 nextpointtx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPX372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07563829 ↗ |
| Route | Intravenous | “Participants who are treated will receive an intravenous (IV) infusion of NPX372” NCT07563829 ↗ |